18.18
2.02%
0.32
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché TVTX Giù?
Forum
Previsione
Frazionamento azionario
Travere Therapeutics Inc Borsa (TVTX) Ultime notizie
Oppenheimer & Co. Inc. Acquires New Stake in Travere Therapeutics, Inc. (NASDAQ:TVTX) - MarketBeat
Kidney Disease Leader Travere Therapeutics Pulls Back To Key Level - Yahoo! Voices
Travere: Q3 Earnings Snapshot - AOL
Los Angeles Capital Management LLC Has $391,000 Stock Position in Travere Therapeutics, Inc. (NASDAQ:TVTX) - MarketBeat
When (TVTX) Moves Investors should Listen - Stock Traders Daily
Exploring Three High Growth Tech Stocks in the United States - Simply Wall St
ARMISTICE CAPITAL, LLC Acquires Significant Stake in Travere The - GuruFocus.com
Woodline Partners LP Expands Stake in Travere Therapeutics Inc - GuruFocus.com
Deep Track Capital, LP Reduces Stake in Travere Therapeutics Inc - GuruFocus.com
Travere Therapeutics (NASDAQ:TVTX) Price Target Raised to $22.00 - MarketBeat
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Travere Therapeutics Awards 24,400 RSUs to New Employees in Talent Acquisition Push | TVTX Stock News - StockTitan
Alport Syndrome Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Eloxx Pharmac, Biogen, River 3 Renal Corp, Travere Therapeutics, Chinook Therapeutics - The Globe and Mail
Travere Therapeutics Completes $143.8 Million Public Offering - Marketscreener.com
Travere Therapeutics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares - The Manila Times
3 Under-the-Radar Healthcare Companies - sharewise
3 Under-the-Radar Healthcare Companies to Watch - MarketBeat
Unitedhealth Group Inc (UNH-N) QuotePress Release - The Globe and Mail
Travere Therapeutics, Inc. (NASDAQ:TVTX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Travere Therapeutics (NASDAQ:TVTX) Reaches New 12-Month HighHere's What Happened - MarketBeat
TVTX stock soars to 52-week high, hits $19.29 amid robust gains - Investing.com India
Latham & Watkins Advises on Travere Therapeutics’ Public Offering of Common Stock - Latham & Watkins LLP
Travere Therapeutics plans public stock offering By Investing.com - Investing.com Australia
Travere Therapeutics Announces Pricing of Public Offering of Common Stock - The Manila Times
Travere Therapeutics Announces Pricing of Public Offering of Common Stock - Benzinga
Travere Therapeutics plans public stock offering - Investing.com India
Travere Therapeutics Launches Public Stock Offering, Led by Jefferies & Leerink | TVTX Stock News - StockTitan
Travere Therapeutics' SWOT analysis: filspari approval boosts rare disease stock outlook - Investing.com UK
Vanguard Group Inc's Strategic Acquisition in Travere Therapeuti - GuruFocus.com
Travere Therapeutics (TVTX) Reports Q3 Loss, Tops Revenue Estimates - MSN
Travere Therapeutics to Present at Upcoming Investor Conferences - The Manila Times
Travere Therapeutics, Inc. (NASDAQ:TVTX) Holdings Raised by Emerald Mutual Fund Advisers Trust - MarketBeat
Travere Therapeutics (NASDAQ:TVTX) Stock Price Expected to Rise, Scotiabank Analyst Says - Defense World
TVTXTravere Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Scotiabank Forecasts Strong Price Appreciation for Travere Therapeutics (NASDAQ:TVTX) Stock - MarketBeat
Evercore ISI raises Travere Therapeutics target to $33 By Investing.com - Investing.com Australia
Travere Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Travere Therapeutics, Inc. (NASDAQ:TVTX) Q3 2024 Earnings Call Transcript - Insider Monkey
Travere Therapeutics Inc (TVTX) Q3 2024 Earnings Call Highlights: Strong Sales Growth Amid Operational Challenges - GuruFocus.com
Travere Therapeutics Boosts Sales with FILSPARI Approval - TipRanks
Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Shares Bounce 27% But Its Business Still Trails The Industry - Simply Wall St
Travere Therapeutics earnings beat by $1.34, revenue topped estimates - Investing.com Australia
Travere Therapeutics Inc Reports Q3 2024 Revenue of $62.9 Millio - GuruFocus.com
Travere Therapeutics Reports Third Quarter 2024 Financial Results - The Manila Times
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):